Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $127.33, giving the company a market capitalization of 157.8B. It carries a P/E multiple of 19.22 and pays a dividend yield of 2.5%.
During the trading session on 2025-11-19, Gilead Sciences(GILD) shares reached a daily high of $127.36 and a low of $123.32. At a current price of $127.33, the stock is +3.3% higher than the low and still -0.0% under the high.
Trading activity shows a volume of 8.18M, compared to an average daily volume of 7.12M.
The stock's 52-week range extends from a low of $86.08 to a high of $127.68.
The stock's 52-week range extends from a low of $86.08 to a high of $127.68.
GILD News
Gilead (GILD) announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as...
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our P/B Growth Invest...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Gilead Sciences, retaining the price target of $135.00. Meet Your ETF AI Analyst Discover how T...
Analyst ratings
71%
of 31 ratingsMore GILD News
Gilead Sciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer from Needham maintained a Buy rating on th...
Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adu...
